CREATING HEALTHCARE WITH
SCIENCE & DIGITAL TECHNOLOGY
CureOmics is a life science company dedicated to improve therapeutic and preventive options for the treatment of unmet healthcare needs. Our research & development is tailored to create digital innovations, novel pharmaceuticals and specialized food-supplement products. Separated from own R&D, the company offers management consulting services to strategic partners.
01 / RESEARCH
CureOmics pursues R&D for digital innovations, drug products and specialized food-supplements.
Our research mission is largely focused around digital innovation. We are addressing major challenges of today's drug product development process and improves patients experience during disease treatment. CureOmics is crossing borders of traditional healthcare solutions and integrates information technologies as central tool to create insight.
Our digital solutions are designed for improving the safety and efficacy profiles of drug treatments during the product development process.
02 / PIPELINE
CureOmics' development of drug products and specialized food-supplements employs cutting edge life-science for translating molecular solutions into a pipeline of novel health care options.
We use a broad spectrum of data to isolate opportunities that positively impact the treatment or prevention of diseases.
For efficient and scalable operations, CureOmics cooperates with established third party partners for formulation development and manufacturing.
03 / CONSULTING
Separated from our research and development operations, we aim to support partners through tailored approaches to create business success. CureOmics' management consulting services for pharmaceutical, nutrition and medicinal product sectors include:
Licensing deal & partnering
Drug substance & drug product development
GxP and regulatory affairs
CMO & CRO services
CureOmics has entered strategic CRO and CMO partnerships in Europe, India and China offering with these partners the development of innovative biologics, biosimilars and small molecule therapies.
In organs, single cells are highly specialized in its subcellular and molecular organization enabling the tissue to manage efficiently complex tasks with outstanding performances. CureOmics adopts this principle of integrated expertise and builds separated business-nuclei being operational independent, highly specialized, efficient, and organized under the umbrella of a greater functional structure. Our separated development programs are segmented into the following business-nuclei:
We are committed to bring together the best of science and technology and aim to build breakthrough knowledge.
Our work is inspired by creating complementing solutions for drug innovation & nutrition. We transfer disruptive ideas into tools that support operational evolution and improve success rates.
Extend the forefront of science
Lead innovation beyond existing solutions
Employ best technologies
Be good and do good
Dr. Stebler is the Chief Executive Officer of CureOmics. He has 15 years of experience in the biotechnology and pharmaceutical industry and worked for Kuros Biosurgery, Xeltis, Novartis, and API suppliers. Dr. Stebler is a scientist and economist who has dedicated his career during past years to improve the lives of people with serious diseases. His experience spans clinical and non-clinical research whereas he was also leading teams in business development, GMP manufacturing, regulatory affairs, quality assurance and intellectual property.
Dr. Stebler holds a PhD in Molecular Biology from the Max Planck Institute & University of Göttingen, a MBA from the IE Business School Madrid, a B.Sc. in Chemistry and is certified in Plant-Based Nutrition from the T. Colin Campbell Center for Nutrition Studies. His executive educations in Decision Analysis from Stanford University and Digital Business Strategy from the Massachusetts Institute of Technology will additionally serve CureOmics to achieve the strategic and operational objectives.
DR. JÜRG STEBLER, MBA